For research use only. Not for therapeutic Use.
Ebrotidine (Cat.No:I000109) is a medication belonging to the class of histamine H2 receptor antagonists. It is primarily used in the treatment of gastric and duodenal ulcers by reducing stomach acid secretion. Ebrotidine helps promote ulcer healing and provides relief from associated symptoms such as pain and discomfort.
| Catalog Number | I000109 |
| CAS Number | 100981-43-9 |
| Synonyms | N-(4-bromophenyl)sulfonyl-N/’-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]methanimidamide |
| Molecular Formula | C14H17BrN6O2S3 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IC50 | 127.5 nM (Ki)[1]; 0.21mg/kg (ED50, histamine- stimulated acid secretion) [2] |
| IUPAC Name | N-(4-bromophenyl)sulfonyl-N'-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]methanimidamide |
| InChI | InChI=1S/C14H17BrN6O2S3/c15-10-1-3-12(4-2-10)26(22,23)19-9-18-5-6-24-7-11-8-25-14(20-11)21-13(16)17/h1-4,8-9H,5-7H2,(H,18,19)(H4,16,17,20,21) |
| InChIKey | ZQHFZHPUZXNPMF-UHFFFAOYSA-N |
| SMILES | C1=CC(=CC=C1S(=O)(=O)NC=NCCSCC2=CSC(=N2)N=C(N)N)Br |
| Reference | </br>1:Determination of ebrotidine and its metabolites by micellar electrokinetic capillary chromatography. Sentellas S, Puignou L, Galceran MT.J Chromatogr A. 2002 Nov 8;976(1-2):221-7. PMID: 12462613 </br>2:Determination of ebrotidine metabolites in overlapping peaks from capillary zone electrophoresis using chemometric methods. Sentellas S, Saurina J, Hernández-Cassou S, Galceran MT, Puignou L.Electrophoresis. 2001 Jan;22(1):71-6. PMID: 11197182 </br>3:Determination of ebrotidine and its metabolites by capillary electrophoresis with UV and mass spectrometry detection. Sentellas S, Puignou L, Moyano E, Galceran MT.J Chromatogr A. 2000 Aug 4;888(1-2):281-92. PMID: 10949494 </br>4:Liver injury caused by ebrotidine: a new example of the utility of the postmarketing surveillance. Castillo JR, Torelló J, Hernandez A.Eur J Clin Pharmacol. 2000 May;56(2):187-9. No abstract available. PMID: 10877015 </br>5:Prevention and healing of experimental indomethacin-induced gastric lesions: effects of ebrotidine, omeprazole and ranitidine. Arroyo MT, Lanas A, Sáinz R.Eur J Gastroenterol Hepatol. 2000 Mar;12(3):313-8. PMID: 10750652 </br>6:[Hepatoxicity due to ebrotidine: report of two cases]. Quílez C, Palazón JM, Jover R, Martínez R, Chuliá T, Griñó P, Belda G.Gastroenterol Hepatol. 1999 Oct;22(8):434-5. Spanish. No abstract available. PMID: 10592681 </br>7:Effect of ebrotidine on gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide. Slomiany BL, Piotrowski J, Slomiany A.J Physiol Pharmacol. 1999 Sep;50(3):391-404. PMID: 10574469 </br>8:Rapid progression to liver cirrhosis of toxic hepatitis due to ebrotidine. Pineda JA, Larrauri J, Macías J, Hernández A, Guijarro J, Sayago M, Gavilán F, Aguilar J, Lissen E.J Hepatol. 1999 Oct;31(4):777-8. No abstract available. PMID: 10551406 </br>9:Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist. Andrade RJ, Lucena MI, Martin-Vivaldi R, Fernandez MC, Nogueras F, Pelaez G, Gomez-Outes A, Garcia-Escaño MD, Bellot V, Hervás A, Cárdenas F, Bermudez F, Romero M, Salmerón J.J Hepatol. 1999 Oct;31(4):641-6. PMID: 10551387 </br>10:Allergic dermatitis due to oral ebrotidine. Carretero Aníbarro P, Blanco Carmona J, García González F, Garcés Sotillos M, Herrero Gil D, Pérez Giménez R, Juste Picón S.J Investig Allergol Clin Immunol. 1999 May-Jun;9(3):193-4. PMID: 10412683 |
